The biopharma reported disappointing fourth-quarter results, missing bottom line estimates amid a steep decline in COVID-19 ...

Nasal vaccine devices have the potential to offer more convenient and more effective protection against a variety of viruses.

Moderna is now expecting 2025 research and development costs of about $4.1 billion and selling, general and administrative costs of about $1.1 billion. Cost of sales is expected to come to about $1.2 ...

Biotech firm Moderna reported a bigger-than-expected quarterly loss on Friday, hit by a charge related to its efforts to ...

Happy V-Day! Gorge on heart-shaped chocolate and ponder the implications of RFK Jr. being sworn in as health secretary. Today, we talk about that, as well as new cancer data from Corbus Pharma, Europe ...

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizing ...

It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the ...

Moderna Inc.'s stock fell 2.9% early Friday, after the biotech posted a wider-than-expected fourth-quarter loss and offered soft guidance for 2025, offsetting a revenue beat.

Robert F. Kennedy Jr. was confirmed Thursday as President Trump’s health secretary amidst several ethics and disinformation ...

In Colorado, vaccine hesitancy is already an issue. CDC data shows in the 2023-2024 school year, Colorado ranked 45/50 for the percentage of kindergartners vaccinated for polio. The state ranked 44th ...

America’s health has been declining for decades. The road was rocky through confirmation but new Secretary of HHS Robert F. Kennedy Jr. plans changes to reverse the trend.

The Senate on Thursday confirmed Robert F. Kennedy Jr. as President Donald Trump’s health secretary, putting the ...